Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such...
April 13, 2026 10:42 ET | Source: Spherix Global Insights

SLE Market Evolution Accelerates as AstraZeneca’s Saphnelo SC Emerges as a Likely Key Challenger to GSK’s Benlysta

Exton, PA, April 13, 2026 (GLOBE NEWSWIRE) -- The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying...
April 13, 2026 08:30 ET | Source: ALX Oncology

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13,...
April 13, 2026 04:32 ET | Source: Research and Markets

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics

Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ...
April 13, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables...
April 11, 2026 07:00 ET | Source: BioNTech SE

BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs

BioNTech gab heute positive Ergebnisse aus der primären Analyse einer Phase-2-Kohorte mit Trastuzumab Pamirtecan bei HER2+ Gebärmutterkrebs bekannt.
April 11, 2026 07:00 ET | Source: BioNTech SE

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
April 09, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight

New York, USA, April 09, 2026 (GLOBE NEWSWIRE) -- Acute Respiratory Distress Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 40+ Key Companies | DelveInsight The...
April 09, 2026 07:00 ET | Source: Rani Therapeutics, LLC

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
April 08, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

New York, USA, April 08, 2026 (GLOBE NEWSWIRE) -- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of...